Review Article
PPAR Agonists: Potential as Therapeutics for Neovascular Retinopathies
Table 1
Growth factors, cytokines, chemokines, and
other proinflammatory mediators downregulated by PPAR activation. PDGF-BB, platelet-derived
growth factor-BB homodimer; AP-1, activated protein-1; NF-κB = nuclear factor-κB;
NFAT = nuclear factor of activated T lymphocytes; STAT = signal transducer and
activator of transcription; ICAM, intracellular adhesion molecule; VCAM,
vascular cell adhesion molecule; iNOS, inducible nitric oxide synthase. (Adapted with permission from: B. Staels, "PPARγ and atherosclerosis." Current Medical Research and Opinion, vol. 21, Suppl. 1, pp. S13-S20, 2005; H. A. Pershadsingh, “Dual peroxisome proliferator-activated receptor-alpha/gamma agonists : in the treatment of type 2 diabetes mellitus and the metabolic syndrome.” Treatments in Endocrinology, vol. 5, no. 2, pp. 89-99, 2006.)
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||